<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01277445</url>
  </required_header>
  <id_info>
    <org_study_id>01B46-10-0156</org_study_id>
    <secondary_id>NDI: 2510.10</secondary_id>
    <nct_id>NCT01277445</nct_id>
  </id_info>
  <brief_title>Effects of Fructan Prebiotics on the Intestinal Microbiota</brief_title>
  <official_title>Evaluation of the Effects of Fructan Prebiotics on the Intestinal Microbiota in Humans: Human Clinical Feeding Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dan Ramdath</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Advance Foods and Materials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ontario Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lethbridge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guelph Food Research Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prebiotics are carbohydrate polymers believed to improve health by stimulating beneficial
      gastrointestinal microbial populations. Prebiotic health claims are currently not permitted
      in Canada due to a lack of validating scientific data. Currently, Health Canada considers
      'prebiotic' to imply a health benefit that must be substantiated. Our goal is to conduct a
      human clinical trial to define the impacts of fructans on the colonic microbiome as well as
      the physiological, psychological and immunological effects on the host.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current health claims for the fructan prebiotics focus on the bifidogenic properties of these
      substrates. While these claims appear to be widely accepted among nutritionists, the
      gut-microbiology community considers this an archaic view on these complex communities which
      contain in excess of 400 species of which the majority have yet to be cultivated or
      characterized. The bifidogenic effect associated with fructans also forms the basis of
      current prebiotic health claims in Canada, claims which up until now have not stood up to
      regulatory scrutiny The primary objective of this study is to assess the impact of frucans on
      the human microbiome, as well as the physiological, immunological health of the host.
      Information generated from this study will address both aspects of the current FOA definition
      of what constitutes a &quot;prebiotic&quot;. New data generated from this study will be applicable for
      a new health claim for prebiotics and will provide a guide for industry demonstrating the
      requirements for a scientifically valid study for other submissions involving prebiotics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in gut microbiota</measure>
    <time_frame>28 days</time_frame>
    <description>various culture and non-culture methods, including molecular biology techniques will be used to determine the type and relative abundance of the gut microbione of persons fed a prebiotic compared with placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Immunological Status</measure>
    <time_frame>28 days</time_frame>
    <description>Circulating levels of cytokines associated with pro-inflammatory status and regulatory activity as well as those associated with TH1 and TH2 activity will be measured. Effects of fructans on cell population profiles in the immune system will also be determined from whole peripheral blood samples, using antibodies against B and T cells, T cell subsets, Natural Killer cells, monocytes, neutrophils and dendritic cells (DC), (including CD3, CD14, CD16, CD19, CD20, CD56)and analyzing by flow cytometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood lipids</measure>
    <time_frame>28 days</time_frame>
    <description>Blood samples will be used to assess cardiovascular disease profiles and standard biochemical biomarkers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Study Focus is to Define the Usual Gut Microbiota Following Prebiotic Feeding</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>15g/day maltodextrin for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prebiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Consumption of 15g/day of inulin-fructan for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prebiotic</intervention_name>
    <description>Inulin-fructan 15mg/day for 28days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prebiotic</intervention_name>
    <description>Daily consumption of 15g inulin-fructan for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Prebiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 - 50 years

          -  General good health

          -  Participant understands the study procedures and provides informed consent (signed) to
             participate and authorizes the release of relevant protected health information to the
             study investigators

        Exclusion Criteria:

          -  History or presence of GI disorders (Irritable bowel syndrome, colitis, Crohn's
             disease, colon cancer or polyps)

          -  Recent use of antibiotics

          -  Regular use of high inulin containing food products.

          -  Known intolerance or sensitivity to any ingredients in the study product.

          -  BMI &gt;30
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Ramdath, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Guelph Food Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Kalmokoff, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Agriculture and Agri-Food Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Traplin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nutrasource Diagnostic Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maggie Laidlaw, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nutrasource Diagnostic Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nutrasoource Diagnostic Inc</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1G 0B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.agr.gc.ca/index_e.php</url>
    <description>Agriculture and Agri-Food Canada</description>
  </link>
  <reference>
    <citation>Gourgue-Jeannot et al. 2006. Can. J. Microbiol. 52:924-933. Brooks et al. 2009. Anaerobe 15:145-154. Costa et al. 2009 J. Microbiol. Methods 78:175-180. Lupton et al. J Nutr. 2004 134:479-82. Gibson and Roberfroid. 1995. J Nutr. 125:1401-12. Parracho et al. 2007. Proc. Nutr Soc. 66:405-11. Eckburg et al. 2005. Science 308:1635-8. Brooks et al. 2003. Can J. Microbiol. 49:589-601. Kelly et al. 2005 Trends Immunol. 26:326-33. Liu et al. 2008. Proc Natl Acad Sci U S A. 105:3951-6. Tsuji et al. 2008. Semin Immunol. 20:59-66. Reigstad et al. 2009 PLoS One 4:e5842. Jenkins et al. 2005. Metabolism 54:103-12. Jenkins et al. 1999. J. Nutr. 129:1431S-1433S. Seidel et al, 2007. Br. J. Nutr. 97:349-356. DiPenta et al. 2007. Appl.Physiol. Nutr.Metabol. 32:1025-1035. Albers et al. 2005. Br. J. Nutr. 94:452-481. Suzuki et al. 2007. Sem. Imm. 19: 127-135. Macpherson et al. 2004. Science 303: 1662-1665. Maino et al. 2004. Clinical Immunol. 110: 222- 231. Coombes and Powrie 2008. Nature Reviews Immunology 8: 435-446. Bakkerk-Zierikzee et al. 2006. Pediatr Allergy Immunol 17:134-140. Svedlund et al. 1988. Digestive Dis. &amp; Sci. 33:129-134. Francka et al., 2005. Allergy Immunol. 136:155-158.</citation>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guelph Food Research Centre</investigator_affiliation>
    <investigator_full_name>Dan Ramdath</investigator_full_name>
    <investigator_title>Research Scientist</investigator_title>
  </responsible_party>
  <keyword>gut microbiome</keyword>
  <keyword>prebiotics</keyword>
  <keyword>immunological status</keyword>
  <keyword>fructans</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

